Key Takeaways
- • Blackstone reported record distributable earnings of $1.75 per share in Q4 2025, marking the highest performance in the firm's 40-year history, with total assets under management reaching $1.3 trillion (up 13% year-over-year).
- • Fourth-quarter inflows reached $71 billion, the highest level in 3.5 years, with 2025 total fundraising of $43 billion from fundraising and perpetual capital sectors up 53% year-over-year.
- • Blackstone Life Sciences Fund VI closed at $6.3 billion (up 40% from Fund V), becoming the largest private equity fund in the life sciences sector, supported by the platform's $15 billion in operating assets and track record of 215+ approved drugs.
- • Total 2025 investments reached $138 billion (largest in four years), positioning Blackstone to capitalize on AI-driven private equity opportunities and easing capital costs in a recovering global trading environment.
- • Institutional and insurance clients representing 75% of Blackstone's credit platform AUM continue to commit large-scale capital despite market sentiment headwinds affecting alternative asset managers sector-wide.
Summary
Blackstone, the world's largest alternative investment manager, reported record financial performance for 2025, driven by exceptional capital inflows and deployment across its core business lines. According to fourth-quarter results released on March 30, 2026, the firm achieved distributable earnings of $1.75 per share—an all-time high—while total assets under management surged to approximately $1.3 trillion, representing 13% year-over-year growth. Chairman and CEO Stephen Schwarzman highlighted the milestone, stating the firm delivered "the best performance in the company's 40-year history" through strong execution in infrastructure, private equity, and the Blackstone Multi-Asset Investment platform.
Inflow momentum accelerated sharply in the fourth quarter, with $71 billion in new capital commitments—the highest quarterly intake in 3.5 years. Full-year 2025 fundraising from the Perpetual Capital and fundraising segments totaled $43 billion, up 53% annually, reflecting sustained demand from institutional investors, insurance companies, and individual investors. This capital influx enabled Blackstone to deploy a total of $138 billion in investments during 2025, marking the largest annual deployment in the preceding four years and positioning the firm to capture long-term value creation opportunities.
The Blackstone Life Sciences platform demonstrated particular momentum, with its flagship Fund VI closing at the hard cap of $6.3 billion—representing a 40% increase from its predecessor fund and making it the largest private equity fund in the life sciences sector. The platform, which manages approximately $15 billion in operating assets, has supported the development of more than 215 drugs to date and executed approximately $2 billion in new investments over the past 12 months, including collaborations with Merck on advanced therapeutics.
Despite sector-wide headwinds affecting alternative asset managers—driven by concerns over software sector valuations, AI disruption, and lending standards—Blackstone's executives defended the private credit asset class. CEO Schwarzman noted that institutional and insurance clients, representing 75% of the credit platform's AUM, have maintained large-scale capital commitments to private credit. COO John D. Gray attributed strong performance to the global trading environment entering a "full-fledged recovery phase" supported by easing capital costs and abundant private equity opportunities emerging from the AI revolution, creating tailwinds for continued growth across debt and equity investments.
Inflow momentum accelerated sharply in the fourth quarter, with $71 billion in new capital commitments—the highest quarterly intake in 3.5 years. Full-year 2025 fundraising from the Perpetual Capital and fundraising segments totaled $43 billion, up 53% annually, reflecting sustained demand from institutional investors, insurance companies, and individual investors. This capital influx enabled Blackstone to deploy a total of $138 billion in investments during 2025, marking the largest annual deployment in the preceding four years and positioning the firm to capture long-term value creation opportunities.
The Blackstone Life Sciences platform demonstrated particular momentum, with its flagship Fund VI closing at the hard cap of $6.3 billion—representing a 40% increase from its predecessor fund and making it the largest private equity fund in the life sciences sector. The platform, which manages approximately $15 billion in operating assets, has supported the development of more than 215 drugs to date and executed approximately $2 billion in new investments over the past 12 months, including collaborations with Merck on advanced therapeutics.
Despite sector-wide headwinds affecting alternative asset managers—driven by concerns over software sector valuations, AI disruption, and lending standards—Blackstone's executives defended the private credit asset class. CEO Schwarzman noted that institutional and insurance clients, representing 75% of the credit platform's AUM, have maintained large-scale capital commitments to private credit. COO John D. Gray attributed strong performance to the global trading environment entering a "full-fledged recovery phase" supported by easing capital costs and abundant private equity opportunities emerging from the AI revolution, creating tailwinds for continued growth across debt and equity investments.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.